Clinical safety surveillance study of the safety and efficacy of long-term home treatment with ReFacto® utilizing a computer-aided diary: A Nordic multicentre study

Haemophilia

Volumn 15, Issue 1, 2009, Pages 175-183

  Petrini, Pia ^a   Rylander, C ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b BIOVITRUM AB   (Sweden)

Author keywords

Efficacy; Electronic device; Factor VIII; Home treatment; ReFacto; Safety

Indexed keywords

ANALGESIC AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 8; TRANEXAMIC ACID;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; HEMOPHILIA A; HOME CARE; HUMAN; INFANT; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; PAIN; PATIENT COMPLIANCE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; SELF MEDICATION; SUBSTITUTION THERAPY; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HOME CARE SERVICES, HOSPITAL-BASED; HUMANS; INFANT; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; RECOMBINANT PROTEINS; SELF ADMINISTRATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 63049122527     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01863.x     Document Type: Article

References (10)

1. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. Semin Hematol 2001; 38(Suppl. 4): 44-51.
2. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. Semin Hemotol 2001; 38(Suppl. 4): 52-9.
3. Lusher JM, Lee CA, Kessler CM, Bedrosian CL, ReFacto Phase 3 Study Group. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9: 38-49.
4. Smith MP, Giangrande P, Pollman H et al. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A. Haemophilia 2005; 11: 444-51.
5. Collins PW, Bolton-Maggs P, Stephenson D, Jenkins B, Loran C, Winter M. Pilot study of an internet-based electronic patient treatment record and communication system for haemophilia, Advoy.com. Haemophilia 2003; 9: 285-91.
6. Petrini P, Berntorp E, Glomstein A et al. Hand computer and internet for collection and presentation of patient diary data in a Nordic clinical multi-center safety surveillance study on Refacto®. Poster presented at XIX Congress of the International Society on Thrombosis and Haemostasis, 12-18 July 2003, Birmingham, UK.
7. Lassila R, Rothschild C, de Moerloose P et al. Recommendations for postmarketing surveillance studies in haemophilia and other bleeding disorders. Haemophilia 2005; 11: 353-9.
8. Pollmann H, Externest D, Ganser A et al. Efficacy, safety and tolerability of recombinant factor VIII (ReFacto®) in patients with haemophilia A: Interim data from a postmarketing surveillance study in Germany and Austria. Haemophilia 2007; 13: 131-43.
9. Lindvall K, Colstrup L, Wollter I-M et al. Compliance with treatment and understanding of own disease in patients with severe and moderate haemophilia. Haemophilia 2006; 12: 47-51.
10. Petrini P Home treatment diaries - for whom? Poster presented at World Federation of Hemophilia, 17-21 October 2004, Bangkok, Thailand.